Novel Biomarker Detects Alzheimer’s Before Onset of Symptoms

Magnetoencephalography biomarker detects preclinical and clinical Alzheimer’s disease based on sensory gating mechanisms.

Alzheimer’s disease - Causes, Symptoms, Diagnosis, Stages, Types, Prevention, Prognosis & Treatment
Alzheimer's disease is a progressive neurodegenerative disease affecting memory and thinking and making the person increasingly dependent on others.

‘Magnetoencephalography, a non-invasive brain imaging technique, used as a biomarker to detect Alzheimer’s disease even before onset of clinical symptoms. ’

Highlights:

Magnetoencephalography (MEG), a non-invasive brain imaging technique, was used as a discrete biomarker to detect preclinical Alzheimer’s disease (AD).
Auditory oddball paradigm was used to study the ability of brain to modulate its response based on the auditory stimuli.
This biomarker will allow detection of AD even before the onset of the first symptom.

A new potential biomarker used to independently detect pathology in Alzheimer’s disease (AD) has been revealed in a study. The biomarker is the magnetoencephalography (MEG) localization of a gating generator at a part of the brain called the medial prefrontal cortex (mPFC). The study is published in the journal Human Brain Mapping.

MEG localization of a mPFC gating generator as a discrete (binary) detector of AD at the

Biomarker Highlights

Non-invasive
Detects illness before onset of symptoms
Does not require standardization
Low sensitivity to individual variability
Tracks pathophysiological process of AD progression

Predicting Alzheimer’s Disease Risk – Multiple Gene Testing Better Than APOE Gene Testing Alone
Polygenic testing of multiple gene variants can more accurately predict cognitively normal adults who may be at a higher risk of developing Alzheimer’s disease

Alzheimer’s and Current Biomarkers

Several studies have shown that the pathological changes associated with AD start years before the actual onset of clinical symptoms. This period where the symptoms have not yet surfaced is called the preclinical stage of the disease. By the time that the disease reaches the clinical stage, the neurodegeneration is irreversible. This accounts for the failure to develop successful therapies.

Current state of the art diagnostic techniques has several limitations, including lumbar puncture, time constraints of scanning and exposure to radiation.

Sanja Josef Golubic found the location of the key - it was hidden in the topography of auditory sensory gating network. She uncovered a topological biomarker of preclinical and clinical AD pathology at the individual level that shows a large effect size (0.98) and high accuracy, sensitivity and specificity (100%) in identifying symptomatic AD patients within a research sample.

"In the present study, we demonstrate the use of the localization of neural sources underlying neuromagnetic fields measured outside a head to detect AD even before the onset of symptoms. The healthy controls activated a prefrontal generator in response to both the deviant and repeating tones of an oddball paradigm. To the contrary, the symptomatic AD group was lacking any medial prefrontal gating generator activation to either the deviant or repeating tones. However, we detected a sub-group of controls characterized by the absence of prefrontal gating generator activation for the repeating tone only and significantly lower scores on a mini-mental status exam and delayed visual memory test - Rey-Osterreith Complex Figure Test. It is highly probable that these individuals were captured in a preclinical AD phase since they show both neuropsychological and neurophysiological impairments characteristic of an AD type of dementia, although they did not yet meet clinical criteria for the early phase of symptomatic AD"

Study Sheds Light on Brain Mechanism Responsible for Visual Information Processing
Neuronal encoding and maintenance of subliminal images is more substantial than previously thought.

Auditory Gating out Generator

Auditory gating out is a process by which one gets habituated to redundant sounds preventing overload of information. Dysfunction of this gating out mechanism or gating generator causes synaptic disturbances contributing to the first symptoms of AD pathology.

The Study and its Findings

MEG is a direct measure of neuronal activity is used as a biomarker to localize the gating generator which is located in the medial prefrontal cortex (mPFC), called the mPFC gating generator.

Using the oddball paradigm, two tones, standard and deviant were played to the participants based on which the MEG localized the activity of the mPFC gating generator.

In healthy controls: mPFC generator localized to both tones
In symptomatic/clinical AD patients:

(1) controls with mPFC generator localized in response to both the standard and deviant tones; (2) a possible preclinical stage of AD participants (a lower functioning group of controls) in which mPFC activation was localized to the deviant tone only; and (3) symptomatic AD in which mPFC activation was not localized to either the deviant or standard tones.

References:

Ideal biomarker’ detects Alzheimer’s disease before the onset of symptoms - (https://www.eurekalert.org/pub_releases/2017-10/afea-bd100217.php)
Josef Golubic, S., Aine, C. J., Stephen, J. M., Adair, J. C., Knoefel, J. E. and Supek, S. (2017), MEG biomarker of Alzheimer’s disease: Absence of a prefrontal generator during auditory sensory gating. Hum. Brain Mapp., 38: 5180–5194.doi:10.1002/hbm.23724

Source-Medindia